Avalon Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avalon Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26	Closed	-$3.2K	–	468
2024 Q4	$3.2K	Buy	+26	New	+$3.06K	﹤0.01%	395

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Avalon Trust's JAZZ Position: Q1 2025 in Review

Avalon Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 26 shares — an estimated $3.2K sold.

Avalon Trust first reported a position in JAZZ in Q4 2024 and held it in 1 quarter. The position peaked at $3.2K in Q4 2024. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

Avalon Trust reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Avalon Trust sold 26 Jazz Pharmaceuticals shares in Q1 2025, an estimated $3.2K.
Avalon Trust first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Avalon Trust's Jazz Pharmaceuticals position peaked at $3.2K in Q4 2024.
550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Avalon Trust's 13F filing for Q1 2025, filed 9 May 2025.